Skip to main content
Clinical Trials/TCTR20210514006
TCTR20210514006
Recruiting
N/A

Incidence of genetic abnormalities in patients with primary hypereosinophilia

Siriraj Hospital Mahidol University0 sites151 target enrollmentMay 14, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
The patient 18 years and older ,The patients diagnosed with primary hypereosinophilia leukocyte count more than 1,500 per microliter for a period of more than 1 month.
Sponsor
Siriraj Hospital Mahidol University
Enrollment
151
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 14, 2021
End Date
December 30, 2023
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Siriraj Hospital Mahidol University

Eligibility Criteria

Inclusion Criteria

  • 1\) The patients diagnosed with primary hypereosinophilia type white blood cells greater than 1,500 per microliter for a period of more than 1 month
  • 2\) 18 years of age and over
  • 3\) Patients who received the gene test The specific targeted fusion gene panel with hypereosinophilia
  • 4\) was welcomed to join the program by signing.

Exclusion Criteria

  • 1\.The patient was detected from a bacterial infection by antibody detection Research projects in which patients are examined. Incidence of nasopharyngeal carcinoma in patients primary hypereosinophilias 686 / 2563 (IRB2\)
  • 2\.Patients with allergic history
  • 3\.Asthma patients
  • 4\. Patients with immune diseases
  • 5 Patients diagnosed with various cancers are not in peacetime.
  • 6\. History of steroid use in patients with herbs or drugs in the past three months
  • 7\. The patients had a history of adverse events leading to leukocyte disease, hypertension, and xa0;
  • Penicillin, cephalosporin, GM\-CSF, NSAID, ranitidine, isopropanol, isopropanol, alanine, amazillin sulfate, chlorazine, chlorazine Cyclospora

Outcomes

Primary Outcomes

Not specified

Similar Trials